Can IL-2 boost immune cells in HIV patients who failed treatment?

NCT ID NCT00113282

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding Interleukin-2 (IL-2) to standard HIV drugs could increase CD4 immune cells in patients whose current treatment was failing and who had very low CD4 counts (≤200). Fifty-seven adults with HIV-1 took part. The main goal was to see if their CD4 count could rise above 200 after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Interleukin-2 (IL-2)

What this could lead to

If successful, adding IL-2 could help HIV patients with very low immune cells raise their counts and better fight infections.

What could go wrong

This is a small, early-phase trial with only 57 participants. IL-2 can cause side effects, and the benefit may not last or apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Necker service des Maladies Infectieuses

    Paris, 75015, France